These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

117 related items for PubMed ID: 7011737

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Receptor binding properties and biologic activity in vitro of biosynthetic human insulin.
    Keefer LM, Piron MA, De Meyts P.
    Diabetes Care; 1981; 4(2):209-14. PubMed ID: 7011729
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Binding of biosynthetic human insulin to erythrocytes of normal and insulin-dependent diabetic subjects: comparison with pork and human pancreatic insulin.
    Bachmann W, Sieger C, Lacher F, Lotz N.
    Diabetes Care; 1981; 4(2):215-9. PubMed ID: 7011730
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Receptor binding studies and clinical effects of human insulin (recombinant DNA): studies in patients with newly diagnosed type i diabetes, type II diabetes, insulin resistance (type A and type B), insulin antibodies, insulin allergy, and "brittle" diabetes.
    Schlüter KJ, Kerp L.
    Diabetes Care; 1982; 5 Suppl 2():152-60. PubMed ID: 6765528
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Subpopulations of antibodies directed against evolutionarily conserved regions of the insulin molecule in insulin-treated patients.
    Karlsson F, Harrison LC, Kahn CR, Itin A, Roth J.
    Diabetologia; 1982 Dec; 23(6):488-93. PubMed ID: 6759274
    [Abstract] [Full Text] [Related]

  • 16. An appraisal of the role of biosynthetic human insulin in the future treatment of diabetes mellitus.
    Gerich JE.
    Diabetes Care; 1981 Dec; 4(2):262-4. PubMed ID: 7011743
    [Abstract] [Full Text] [Related]

  • 17. Studies on the biologic actions of biosynthetic human insulin in vitro and in diabetic man.
    Waldhäusl WK, Kastner G, Komjati M, Bratusch-Marrain P.
    Diabetes Care; 1981 Dec; 4(2):205-8. PubMed ID: 7011728
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals.
    Schernthaner G, Borkenstein M, Fink M, Mayr WR, Menzel J, Schober E.
    Diabetes Care; 1983 Dec; 6 Suppl 1():43-8. PubMed ID: 6343038
    [Abstract] [Full Text] [Related]

  • 20. Biologic and immunologic in vivo and in vitro studies with biosynthetic human insulin.
    Federlin K, Laube H, Velcovsky HG.
    Diabetes Care; 1981 Dec; 4(2):170-4. PubMed ID: 7011720
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.